Gemfibrozil

吉非罗齐

Report date: 2025/08/18 17:56:36
NME

Base Information

Drug NameGemfibrozil
Drug Alias Name吉非贝齐LopidInnogemLipurLipozid +[9] 
ClassificationSmall molecules
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsSmoking CessationHyperlipoproteinemiasHyperlipidemias +[6] 
Global Approved IndicationsHyperlipoproteinemiasHyperlipidemiasMyocardial Ischemia
Approved Indications in ChinaHyperlipoproteinemiasHyperlipidemias
Original Approved Country/TerritoryUnited States
Original Approved Date1981/12/21
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesForest Hills LabPfizer Pharmaceuticals LlcQian Jin Xiangjiang Pharmageuical Co Led Hunan
Inactive CompaniesUniversity of Texas Southwestern Medical CenterParke-Davis Gmbh
Active IndicationsHyperlipoproteinemiasHyperlipidemiasMyocardial Ischemia +[4] 
Inactive IndicationsSmoking CessationCoronary Disease

Other Information

ATC CodeC10AB04
Related LinksWikipediaDrugBankKEGG